ASCO® 2024 Summary: "Treatment Considerations for Challenging Populations With Hodgkin Lymphoma"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Treatment Considerations for Challenging Populations With Hodgkin Lymphoma"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Cathy Burton

115 views

June 10, 2024

Chapters

Overview & Focus on Older Patients

00:00

Biology & Challenges in Older Patients

01:40

Chemotherapy & Bleomycin Concerns

02:44

Targeted Treatments & Brentuximab Trials

03:56

Efficacy of Brentuximab & Nivolumab

05:48

Treatment Strategies for Unfit & Comorbid Patients

12:27

Conclusions & Future Directions

15:16

Comments 0

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

2024 ASCO® Annual Meeting Insights Hub: Hematologic Oncology Videos

Post-Transplant Cyclophosphamide Based GVHD Prophylaxis in Patients …

ecancer

M. Al Malki, S. Devine

42 views

3 months ago

ASCO® 2024 Insights: "Importance of MRD in Newly Diagnosed Multiple …

ecancer

X. Leleu

77 views

4 months ago

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

704 views

4 months ago

View All

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

3.4K views

8 months ago

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

485 views

3 months ago

ASCO® 2024 Summary: "Treatment of Relapsed HL - Updated Options in L…

2024 ASCO® Annual Meeting Insights Hub

P. Johnson

434 views

5 months ago

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

883 views

7 months ago

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

419 views

1 month ago

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

613 views

6 months ago

Emerging and Current Treatment for Hodgkin Lymphoma in 2024

Indy Hematology Review

S. Ansell

387 views

6 months ago

ASCO® 2023 Insights: "SWOG S1826, a Randomized Study of Nivo-AVD vs.…

Insights from 2023 ASCO® Annual Meeting

A. Herrera

1.2K views

1 year ago

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

304 views

5 months ago

Practice-Changing Abstracts in NHL and HL From ASH 2023

UChicago Medicine

S. Smith

400 views

8 months ago

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

163 views

4 weeks ago

Treatment Updates and Management of Hodgkin Lymphoma

Integrity CE

A. Niu, D. Wallace, M. Cortese

149 views

3 months ago

Key Lymphoma Updates From ASH

Memorial Sloan Kettering Cancer Center

P. Torka

374 views

6 months ago

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Total Health

M. Rotta

240 views

4 months ago

Summary of Recent Updates in Advanced Hodgkin Lymphoma

SOHO Brazil 2024

C. Moskowitz

197 views

4 months ago

ASCO® 2023 Insights: "SWOG S1826 - Rationale, Results, and Clinical …

Insights from 2023 ASCO® Annual Meeting

A. Evens

845 views

1 year ago

EHA 2024 Insights: Treatment of Advanced Stage, High-Risk Hodgkin's …

Insights from 2024 EHA Annual Meeting

M. Salamoon

156 views

4 months ago

Summary of Recent Updates in R/R HL

SOHO Brazil 2024

C. Moskowitz

123 views

4 months ago

NCCN Guidelines for the Treatment of cHL: A New Standard of Care

Stephen M. Ansell

679 views

1 year ago

Early Stage HL: Can Radiation Therapy Be Eliminated?

SOHO Brazil 2024

C. Moskowitz

108 views

4 months ago

AUTOPLAY

Login

Login

Join VuMedi

ASCO® 2024 Summary: "Treatment Considerations for Challenging Populations With Hodgkin Lymphoma"

Overview & Focus on Older Patients

Biology & Challenges in Older Patients

Chemotherapy & Bleomycin Concerns

Targeted Treatments & Brentuximab Trials

Efficacy of Brentuximab & Nivolumab

Treatment Strategies for Unfit & Comorbid Patients

Conclusions & Future Directions

Importance of Early Management of Patients with Myelofibrosis (MF)

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

2024 ASCO® Annual Meeting Insights Hub: Hematologic Oncology Videos

Post-Transplant Cyclophosphamide Based GVHD Prophylaxis in Patients …

ASCO® 2024 Insights: "Importance of MRD in Newly Diagnosed Multiple …

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Recommended

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Current Treatment of 1L Hodgkin Lymphoma

ASCO® 2024 Summary: "Treatment of Relapsed HL - Updated Options in L…

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

ESMO 2024 Summary: Highlights in Heme Malignancies

Top 5 Lymphoma Abstracts From ASH

Emerging and Current Treatment for Hodgkin Lymphoma in 2024

ASCO® 2023 Insights: "SWOG S1826, a Randomized Study of Nivo-AVD vs.…

Practice-Changing Updates in DLBCL and HL

Practice-Changing Abstracts in NHL and HL From ASH 2023

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Treatment Updates and Management of Hodgkin Lymphoma

Key Lymphoma Updates From ASH

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Summary of Recent Updates in Advanced Hodgkin Lymphoma

ASCO® 2023 Insights: "SWOG S1826 - Rationale, Results, and Clinical …

EHA 2024 Insights: Treatment of Advanced Stage, High-Risk Hodgkin's …

Summary of Recent Updates in R/R HL

NCCN Guidelines for the Treatment of cHL: A New Standard of Care

Early Stage HL: Can Radiation Therapy Be Eliminated?